For over 25 years, we have been a trusted leader among imaging CROs. We provide a wide range of blinded clinical trial data assessment and management services, which include assessments of non-imaging subjective data, such as patient outcomes and adverse reactions.
Using rigorous independent review (IR) training and testing paradigms, we minimize and monitor variability of IR data with a cost-efficient adaptive design approach. By taking into account the endpoint measured, type of adjudication and number of adjudication triggers, WCC enhances the precision and accuracy of your blinded independent central review (BICR) data.
With a history of facilitating multi-component trials in a large array of oncology research, including breast, lymphoma, brain, and melanoma trials, WCC has managed to streamline the process for sponsor review in complex environments. We deliver unparalleled workflow flexibility and have experience successfully managing Phase II and III trials with WHO, RECIST 1.0 & 1.1 and CHESON requirements. Most recently we have developed a combined assessment for oncology immunotherapeutics.
EACs in Oncology
Endpoint adjudication committees (EACs) have become increasingly important to the validity of oncology trials due to the complexity of these studies' workflows. Recognizing the importance of providing extensive coverage in workflow management and integration of imaging data with additional clinical components, we deliver a complete subjective assessment that includes clinical listings and pathology.
Our team has extensive clinical trial and scientific expertise using a wide array of brain imaging tools. We leverage large teams of board-certified neuroradiologists, sufficient to cover any size clinical trial. In addition, we have a staff of validated pre-measurers to perform initial lesion assessment. This capability, coupled with our automated brain atrophy and other advanced measuring software, can result in significant cost savings.
Based on the model developed by the Alzheimer's Disease Neuroimaging Initiative (ADNI), WCC has put together a full-service diagnostic assessment program for Alzheimer's disease. Our physicists, neuroradiologists, and clinicians provide comprehensive evaluation of patients from eligibility review through endpoint assessment. Longitudinal evaluation of on-study imaging can include qualitative and quantitative analysis of PET-FDG, SPECT-perfusion, PET-Amyloid imaging and cortical atrophy.
WCC has the capability to perform over 1,000 multiple sclerosis (MS) MRI reads a month. We have an established team of neuroradiologists that we have been working with for more than 10 years and whose MRI interpretations have been validated. This validation includes demonstrating a correlation between patient lesion burden, as determined by MGH neuroradiology, and relapse rate.
Keeping pace with the rapid technological advances of Cardiac Imaging, we offer cutting edge Cardiac Imaging services. In collaboration with leading clinical researchers in Cardiology and Cardiac Imaging, WCC provides full service quantitative cardiac imaging assessments for both right and left heart structure and function. This includes:
- Quantitative MRI
- Quantitative multi-modality assessment for right atrium (PET/MRI , 3-D ECHO)
- CT and MR Angiography
- 2D and 3D ECHO
WCC is experienced in Osteoporosis, Rheumatoid Arthritis, and Osteoarthritis as well as sport medicine injuries. Our Medical Director, Dr. Stephen Pomeranz, is a noted MRI, CT, and PET consultant to professional sports teams around the world and a leading expert in pre- and post-operative implant assessment.
We have experience with DXA, X-Ray, MRI, CT, and MRE in MSK trials. Our analysis and reading capabilities include measurements of bone mineral density, muscle and fat segmentation, fracture scoring, fracture-healing, joint-space width measurements, and more. Our services also include safety monitoring, including bone loss, t-score, z-score, and fracture reporting.